Protalix BioTherapeutics, Inc. (PLX) Bundle
Ever wondered how a biopharmaceutical company can leverage plant cell-based technology to develop innovative medicines? Protalix BioTherapeutics, Inc. (PLX), with a market capitalization of $188.06 million as of April 2025, is doing just that, focusing on recombinant therapeutic proteins for rare diseases and achieving $53.0 million in revenue from selling goods in 2024. Keep reading to discover the fascinating history, ownership structure, mission, and financial strategies that drive this company forward, plus how its unique ProCellEx® platform works and generates revenue.
Protalix BioTherapeutics, Inc. (PLX) History
Protalix BioTherapeutics Founding Timeline
Year established
The company was established in 1993.
Original location
The company's original location was in Carmiel, Israel.
Founding team members
The founding team members included Dr. Yoseph Shaaltiel and Dr. David Aviezer.
Initial capital/funding
Information regarding the company's initial capital and funding during its founding is not readily available in the provided search results.
Protalix BioTherapeutics Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2012 | Elelyso Receives FDA Approval | Elelyso (taliglucerase alfa) for injection, the company’s plant-based enzyme replacement therapy (ERT) for the treatment of Gaucher disease, receives approval from the U.S. Food and Drug Administration (FDA). |
| 2021 | FDA accelerated approval for PElrezza | The U.S. Food and Drug Administration granted accelerated approval to PElrezza (pegunigalsidase alfa-iwxj) for injection, the company’s enzyme replacement therapy (ERT) for the treatment of Gaucher disease. |
Protalix BioTherapeutics Transformative Moments
- FDA Approval of Elelyso (2012): The FDA's approval of Elelyso marked a significant turning point for the company, validating its plant-based protein expression technology, known as ProCellEx, and paving the way for future product development.
- Strategic Partnerships: Forming strategic partnerships with major pharmaceutical companies for the development and commercialization of its products has expanded the company's reach and resources.
- Focus on Rare Diseases: Protalix BioTherapeutics has strategically focused on developing treatments for rare diseases, addressing unmet medical needs and creating opportunities for orphan drug designations and market exclusivity.
- PElrezza Approval (2021): FDA accelerated approval for PElrezza in 2021 significantly bolstered Protalix's portfolio.
To gain more insights into the company's ownership and investor activity, you might find this resource helpful: Exploring Protalix BioTherapeutics, Inc. (PLX) Investor Profile: Who’s Buying and Why?
Protalix BioTherapeutics, Inc. (PLX) Ownership Structure
Understanding the ownership structure of Protalix BioTherapeutics, Inc. provides valuable insights into the company’s governance and strategic direction. A diverse mix of institutional and individual investors currently holds the company's shares.
Protalix BioTherapeutics, Inc.'s Current Status
Protalix BioTherapeutics, Inc. is a publicly traded company, listed on the NYSE American under the ticker symbol PLX. This means that its shares are available for purchase by the general public, and the company is subject to regulations and reporting requirements set forth by the U.S. Securities and Exchange Commission (SEC).
Protalix BioTherapeutics, Inc.'s Ownership Breakdown
The ownership of Protalix BioTherapeutics, Inc. is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders. The following table summarizes the approximate ownership percentages based on the latest available data:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 58.75% | Includes investment firms, hedge funds, and other institutions. |
| Individual Investors | 41.25% | Comprises retail investors and company insiders. |
Protalix BioTherapeutics, Inc.'s Leadership
The leadership team plays a crucial role in guiding the strategic direction and operational execution of Protalix BioTherapeutics, Inc. As of April 2025, the key members of the leadership team include:
- Dror Bashan: President and Chief Executive Officer
- Eyal Rubin: Senior Vice President and Chief Financial Officer
- Einat Brill Almon, Ph.D.: Senior Vice President and Chief Development Officer
- Yael Harel: Vice President, Corporate Development and Licensing
For more insights into the financial health of Protalix BioTherapeutics, Inc., you can explore this analysis: Breaking Down Protalix BioTherapeutics, Inc. (PLX) Financial Health: Key Insights for Investors
Protalix BioTherapeutics, Inc. (PLX) Mission and Values
Protalix BioTherapeutics is dedicated to transforming lives by developing innovative solutions for rare diseases with high unmet needs, driven by an unwavering commitment to patients.
[Company's] Core Purpose
Official mission statement
Protalix BioTherapeutics' mission is to deliver safe and effective solutions to individuals facing limited to no currently available therapeutic options. The company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system.
- Dedicated to bringing to market recombinant therapeutic proteins with clinically improved profiles.
- Focused on therapies for Fabry and Gaucher diseases.
- Expanding pipeline to address the unmet needs of patients facing some of the most challenging rare diseases.
Vision statement
Protalix aims to be at the forefront of transforming lives by developing groundbreaking solutions for rare diseases with high unmet need. The company is committed to expanding its pipeline to address the unmet needs of patients facing some of the most challenging rare diseases.
- Pioneering protein solutions to transform the treatment of rare diseases.
- Exploring next-generation solutions in renal and other therapeutic areas.
- Actively seeking collaborations for its existing pipeline or in developing new therapeutics for rare diseases with high unmet needs.
Company slogan/tagline
Pioneering Protein Solutions to Transform the Treatment of Rare Diseases.
For more in-depth information, check out: Mission Statement, Vision, & Core Values of Protalix BioTherapeutics, Inc. (PLX).
Protalix BioTherapeutics, Inc. (PLX) How It Works
Protalix BioTherapeutics operates by developing and producing recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx. This system allows for the creation of complex proteins that are difficult to produce through traditional methods, targeting niche markets with unmet medical needs.
Protalix BioTherapeutics' Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Elelyso (taliglucerase alfa) | Gaucher disease patients |
|
| pegunigalsidase alfa (PRX-102) | Fabry disease patients |
|
| Alidorn alfa | Treatment of Fabry disease |
|
Protalix BioTherapeutics' Operational Framework
Protalix BioTherapeutics leverages its unique ProCellEx platform to manufacture complex proteins. The company focuses on:
- Research and Development: Continually innovating and expanding its pipeline of recombinant proteins.
- Manufacturing: Utilizing its ProCellEx platform for scalable and cost-effective production.
- Regulatory Affairs: Working closely with regulatory agencies to secure approvals for its products.
- Commercialization: Partnering with established pharmaceutical companies for marketing and distribution in various regions.
These operations are designed to bring novel therapies to market, addressing rare diseases with significant unmet needs. To gain more insights into the company's guiding principles, you can explore: Mission Statement, Vision, & Core Values of Protalix BioTherapeutics, Inc. (PLX).
Protalix BioTherapeutics' Strategic Advantages
Protalix BioTherapeutics possesses several strategic advantages that contribute to its success:
- Proprietary Technology: The ProCellEx platform provides a competitive edge in producing complex proteins.
- Targeting Niche Markets: Focusing on rare diseases reduces competition and addresses critical medical needs.
- Strategic Partnerships: Collaborations with major pharmaceutical companies enhance market reach and commercialization capabilities.
- Experienced Management Team: A team with expertise in protein therapeutics and plant cell-based manufacturing.
These advantages enable Protalix to effectively develop, manufacture, and commercialize its products, driving value for both patients and stakeholders.
Protalix BioTherapeutics, Inc. (PLX) How It Makes Money
Protalix BioTherapeutics generates revenue primarily through the development and commercialization of recombinant therapeutic proteins, focusing on treatments for genetic disorders.
Protalix BioTherapeutics, Inc.'s Revenue Breakdown
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Product Sales (Elelyso) | Approximately 70-80% | Relatively Stable, with fluctuations based on market demand and competition |
| Out-licensing and Royalties | Approximately 20-30% | Increasing, dependent on the success of partnered products and geographic expansion |
Protalix BioTherapeutics, Inc.'s Business Economics
Protalix BioTherapeutics, Inc. operates with a business model centered on developing and commercializing its own proprietary products, as well as out-licensing agreements to expand market reach. Here are key aspects of its business economics:
- Pricing Strategy: Protalix prices its drugs, such as Elelyso, based on the value they provide in treating specific conditions, considering factors like efficacy, patient population, and competitive landscape.
- Cost of Goods Sold (COGS): A significant portion of Protalix's expenses comes from the production of its recombinant proteins, involving cell culture and purification processes.
- R&D Investments: Protalix invests heavily in research and development to discover new therapeutic proteins and improve existing ones.
- Partnerships: Strategic alliances with other pharmaceutical companies help Protalix to share development costs and expand market access.
Protalix BioTherapeutics, Inc.'s Financial Performance
Analyzing Protalix BioTherapeutics, Inc.'s financial performance involves looking at key indicators that reflect its operational efficiency and profitability. Consider these points:
- Revenue Trends: Monitoring the growth in product sales and royalty income helps gauge market acceptance and the success of partnerships.
- Gross Margin: The gross margin indicates the efficiency of Protalix's production processes and pricing strategies.
- Operating Expenses: Managing operating expenses, including R&D and SG&A, is crucial for achieving profitability.
- Cash Flow: Analyzing cash flow from operations, investing, and financing activities provides insights into the company's financial stability and ability to fund future growth.
- Net Income/Loss: The bottom line reflects the overall financial performance and is a key indicator for investors.
For more detailed insights into the financial health of Protalix BioTherapeutics, Inc., you can explore this resource: Breaking Down Protalix BioTherapeutics, Inc. (PLX) Financial Health: Key Insights for Investors
Protalix BioTherapeutics, Inc. (PLX) Market Position & Future Outlook
Protalix BioTherapeutics is strategically positioned within the biopharmaceutical industry, focusing on the development and commercialization of recombinant therapeutic proteins expressed through its plant cell-based expression system, known as ProCellEx. As of April 2025, the company's future outlook hinges on expanding its product pipeline and maximizing the market potential of its existing products.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Protalix BioTherapeutics, Inc. | ~ 3% | Proprietary ProCellEx platform for protein expression; Focus on niche therapeutic areas. |
| Sanofi | ~ 25% | Diversified product portfolio; Extensive global distribution network. |
| Takeda Pharmaceutical | ~ 20% | Strong presence in rare disease market; Established partnerships. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Expanding the label and indications for Taliglucerase alfa (Elelyso) to new markets and patient populations. | Competition from established players in the enzyme replacement therapy market. |
| Advancing the clinical development of OPRX-106 for inflammatory and fibrotic diseases. | Clinical trial failures or delays in regulatory approvals. |
| Securing partnerships and collaborations to expand the product pipeline and market reach. | Reliance on collaborations for funding and development, which may be subject to termination or changes in strategy. |
Industry Position
Protalix BioTherapeutics occupies a niche position within the biopharmaceutical industry, distinguished by its proprietary ProCellEx technology. Key aspects of its industry standing include:
- Innovative Technology: The ProCellEx platform offers a unique approach to protein expression, potentially providing advantages in terms of manufacturing efficiency and protein glycosylation.
- Niche Focus: Protalix concentrates on developing treatments for genetic disorders and inflammatory diseases, allowing it to address unmet medical needs in specific patient populations.
- Strategic Partnerships: Collaborations with larger pharmaceutical companies, such as Chiesi Farmaceutici, enhance Protalix's ability to develop and commercialize its products globally.
To gain more insights into the investors and the rationale behind their investment decisions, check out this resource: Exploring Protalix BioTherapeutics, Inc. (PLX) Investor Profile: Who’s Buying and Why?
Protalix BioTherapeutics, Inc. (PLX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.